✦ LIBER ✦

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis

✍ Scribed by Griffin, James D.; Guerin, Annie; Chen, Lei; Macalalad, Alexander R.; Luo, Jiayuan; Ionescu-Ittu, Raluca; Wu, Eric Qiong

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A retrospective analysis of therapy adhe

✍ Guérin, Annie; Chen, Lei; Wu, Eric Q.; Ponce de Leon, Diego; Griffin, James D. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 174 KB

Lack of non-hematological cross intolera

✍ Yukio Kobayashi; Hisashi Sakamaki; Shin Fujisawa; Kiyoshi Ando; Kazuhito Yamamot 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 152 KB

Dasatinib, even at low doses, is an effe

✍ Giuseppe Visani; Massimo Breccia; Antonella Gozzini; Giorgina Specchia; Enrico M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 640 KB